UPDATE: Jefferies Raises Price Target On NPS Pharmaceuticals Ahead Of Acquisition By Shire

by Benzinga Staff
January 12, 2015 9:00 AM | 1 min read

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

In a report published Monday, Jefferies analyst Eun K. Yang reiterated a Hold rating on NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), and raised the price target from $26.00 to $46.00.In the report, Jefferies noted, “Shire's proposed acquisition of NPSP for ~$5.2B (~25x our estimated 2015 Gattex/Natpara sales) is anticipated to close by 1Q15. Shire notes a calculated risk ahead of Natpara PDUFA date on 1/24/15. The hefty price that Shire is paying for NPSP underscores the premium that marketed/positive Ph3 assets can now command regardless of potential commercial challenges. Setting PT to proposed acquisition price of $46.”NPS Pharmaceuticals closed on Friday at $41.91.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorPrice TargetAnalyst RatingsEun K. YangJefferies

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.